['type 1 diabetes mellitus (t1dm)', 'high level of sugar (glucose) in the blood']
['sotagliflozin', 'placebo']

        Inclusion Criteria:

          -  Participants had given written informed consent to participate in the study in
             accordance with local regulations

          -  Adult participants 18 years and older with a diagnosis of T1DM made at least 1 year
             prior to informed consent

          -  Participants were being treated with insulin or insulin analog

          -  Willing and able to perform self-monitoring of blood glucose (SMBG) and complete the
             study diary as required per protocol

          -  At the Screening Visit, A1C was between 7.0% to 11.0%

          -  Females of childbearing potential used an adequate method of contraception and had a
             negative pregnancy test

        Exclusion Criteria:

          -  Use of antidiabetic agent other than insulin or insulin analog at the time of
             screening

          -  Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to
             screening

          -  Chronic systemic corticosteroid use

          -  Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the
             Investigator
      